Our Pipeline

VDPHL01 is a non-hormonal oral treatment in development for androgenetic alopecia (AGA), also known as pattern hair loss (PHL), in both men and women.

 

If approved, VDPHL01 could become the first FDA-approved oral treatment designed and studied specifically for pattern hair loss that restores hair without the drawbacks of current options.

Pattern hair loss is the most common form of hair loss, affecting 80 million people in the U.S. alone. For many, the progressive loss of hair coverage can significantly impact self-esteem, confidence, and overall well-being.

 

Today, there is no single treatment for pattern hair loss that is both consistently effective and tolerable. Existing treatments offer limited efficacy, with either messy, time-consuming topical applications or unwanted and potentially serious side effects.

 

Despite widespread prevalence, the emotional toll of hair loss and the burden of current treatments,  this common dermatologic condition has seen little innovation with no novel approvals in more than 20 years.

 

VDPHL01 has the potential to fill this critical gap, offering a  consistently effective, convenient, and well-tolerated oral treatment to help individuals living with pattern hair loss.